A composition including endometrial, especially mesenchymal stem cells (EnMSC), for use in a method for the treatment of poor ovarian response and a method for banking endometrial, especially mesenchymal, stem cells.

A composition including endometrial, especially mesenchymal stem cells (EnMSC), for use in a method for the treatment of poor ovarian response and a method for banking endometrial, especially mesenchymal, stem cells.

The present disclosure relates to a method of treating or delaying onset of a disease associated with the accumulation of senescent cells in a subject comprising administering to the subject a therapeutically effective amount of a senosuppressor that modulates a number of ATRX foci per cell.

The present disclosure relates to a method of treating or delaying onset of a disease associated with the accumulation of senescent cells in a subject comprising administering to the subject a therapeutically effective amount of a senosuppressor that modulates a number of ATRX foci per cell.

The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.

The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.

This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.

This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.